Programme Thesis
SPARTNERS Incubator Startup Call by Hello Tomorrow funds pre-seed/early-stage biotech startups with access to fully equipped labs, expert support, and Servier’s network at Paris-Saclay. It exists to accelerate innovations addressing unmet medical needs by providing infrastructure, scientific mentorship, and strategic connections to pharma and academia.
Selection Criteria
- Eligibility: Human health & biotech startups (pre-seed/early-stage) with a clear unmet medical need.
- Priority areas: Oncology, Neurology, Drug discovery platforms (for Golden Ticket).
- Evaluation criteria: Scientific/technical innovation, feasibility, team expertise, alignment with Servier’s strategic areas, potential for impact.
- Scoring rubric: Not publicly detailed; likely based on novelty, proof-of-concept strength, market need, and fit with Servier’s R&D.
- Reviewer priorities: Startups that can leverage Servier’s experimental platforms and benefit from the collaborative ecosystem.
Past Winners / Cohort Profiles
No specific past winners listed on the page. Typical Hello Tomorrow Spartners cohorts include early-stage biotech startups in oncology, neurology, and drug discovery platforms, often with academic or pharma partnerships. Archetypes: spin-offs from Paris-Saclay labs, AI-driven drug discovery, and therapeutic platforms.
Ideal Candidate Fingerprint
A pre-seed biotech startup with a validated proof-of-concept, addressing an unmet medical need in oncology, neurology, or drug discovery. The ideal applicant has a strong scientific team, clear alignment with Servier’s priorities, and a need for lab space and pharma network access to advance their technology.
Recommended Framing
Eniola should position the venture as a drug discovery platform that directly aligns with Servier’s priority areas (oncology, neurology) by predicting drug resistance mutations—a critical unmet need in targeted therapies. Emphasize the Paris-Saclay location, existing connection to Servier (named partner), and the technology’s ability to complement Servier’s R&D platforms. Highlight the proof-of-concept (AUROC 0.804) and the roadmap to fine-tune on SKEMPI for even higher accuracy, framing the incubator as the ideal launchpad for a Servier pilot.
Watch Out
Applicant is not yet incorporated (pre-incorporation may be acceptable for pre-seed but could be a minor hurdle; check if legal entity required). Solo founder status may raise team depth concerns—consider mentioning planned hires or academic collaborators. No mention of wet lab needs; the incubator offers lab benches, so the venture’s computational focus may need to justify physical lab use (e.g., for validation assays).
Research History
2026-07-09 17:56 · medium confidence